Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
34 hedge funds and large institutions have $913K invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
3% more funds holding
Funds holding: 33 → 34 (+1)
50% less capital invested
Capital invested by funds: $1.83M → $913K (-$918K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$71.3K |
| 2 |
Walleye Capital
New York
|
+$17.7K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$3.56K |
| 4 |
SC
Shay Capital
New York
|
+$1.89K |
| 5 |
HF
HRT Financial
New York
|
+$1.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$93K |
| 2 |
ICM
Ionic Capital Management
New York
|
-$10.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.93K |
| 5 |
Jane Street
New York
|
-$1.29K |
DNA.WS Hedge Fund Activity: Q4 2023 in Review
34 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q4 2023, worth a combined $913K — down 50% from $1.83M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DNA.WS positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Cowen and Company, adding an estimated $71.3K. The largest seller was CVI Holdings, exiting entirely with an estimated $93K sold.
- 34 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q4 2023, up from 33 in Q3 2023.
- Funds reported $913K of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q4 2023, down 50% quarter-over-quarter.
- 3 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q4 2023 was Cowen and Company, an estimated $71.3K added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q4 2023 was CVI Holdings, an estimated $93K sold.
Based on aggregated 13F filings for Q4 2023.